Codexis - CDXS Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12 month price objectives for Codexis' stock. Their CDXS share price forecasts range from $19.00 to $25.00. On average, they expect the company's stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 141.3% from the stock's current price.
View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts.

Codexis' stock was trading at $31.27 at the beginning of the year. Since then, CDXS shares have decreased by 71.7% and is now trading at $8.84.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CDXS earnings forecast.

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The biotechnology company had revenue of $38.41 million for the quarter, compared to analyst estimates of $37.86 million. Codexis had a negative net margin of 14.03% and a negative trailing twelve-month return on equity of 11.63%. The firm's quarterly revenue was up 50.9% on a year-over-year basis. During the same period last year, the business earned ($0.07) earnings per share.

Codexis issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $135.00 million-$141.00 million, compared to the consensus revenue estimate of $137.67 million.

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.33%), ARK Investment Management LLC (6.87%), Allspring Global Investments Holdings LLC (4.62%), FMR LLC (2.73%), Assenagon Asset Management S.A. (2.28%) and Sumitomo Mitsui Trust Holdings Inc. (1.70%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXS stock can currently be purchased for approximately $8.84.

Codexis (NASDAQ:CDXS) has a market capitalization of $578.93 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

The company employs 261 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.